Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, France.
Retina. 2010 Mar;30(3):399-406. doi: 10.1097/IAE.0b013e3181bcef24.
The purpose of this study was to evaluate the efficacy of intravitreal injections of ranibizumab in choroidal neovascularization secondary to pathologic myopia.
A prospective case series of 32 eyes of 32 patients affected with choroidal neovascularization secondary to pathologic myopia treated by intravitreal injections of ranibizumab. Best-corrected visual acuity, fundus examination, fluorescein angiography, indocyanine green angiography, and spectral domain-optical coherence tomography were performed for the diagnosis of myopic choroidal neovascularization. Best-corrected visual acuity and central retinal thickness measurement were performed monthly during the follow-up.
The median number of injections was 3 with a median follow-up of 17 months. The median visual acuity at baseline was 20/100 and improved to 20/50 at final examination (P < 0.0001). Best-corrected visual acuity improved by > or = 3 lines in 15 of 32 eyes (46.8%). The median central thickness was 336 microm (range, 179-663 microm) at baseline and 233 microm (range, 125-465 microm) at final examination (P < 0.0001). No severe drug-related side effect was reported.
In our series of myopic choroidal neovascularization, intravitreal injections of ranibizumab showed visual acuity improvement and retinal thickness reduction. Further prospective multicentric clinical trials are needed to evaluate the safety and the efficacy of this treatment.
本研究旨在评估玻璃体内注射雷珠单抗治疗病理性近视脉络膜新生血管的疗效。
前瞻性病例系列研究，共纳入 32 例（32 只眼）接受玻璃体内注射雷珠单抗治疗的病理性近视脉络膜新生血管患者。通过最佳矫正视力、眼底检查、荧光素血管造影、吲哚青绿血管造影和频域光相干断层扫描对近视性脉络膜新生血管进行诊断。在随访期间，每月进行最佳矫正视力和中心视网膜厚度测量。
平均注射次数为 3 次，平均随访时间为 17 个月。基线时的平均视力为 20/100，最终检查时提高至 20/50（P＜0.0001）。32 只眼中，15 只（46.8%）视力提高≥3 行。基线时的平均中央厚度为 336μm（范围，179-663μm），最终检查时为 233μm（范围，125-465μm）（P＜0.0001）。未报告严重与药物相关的不良反应。
在本研究系列中，玻璃体内注射雷珠单抗可改善病理性近视脉络膜新生血管患者的视力和减轻视网膜厚度。需要进一步开展前瞻性多中心临床试验，以评估该治疗方法的安全性和疗效。
